Streamlining your approach to HCC testing

See how the Oncoguard® Liver test integrates into your clinical workflow

A simplified testing pathway for most patients

The Oncoguard® Liver test is a simple, yet sophisticated blood test offering a streamlined approach to HCC testing that can be integrated into your clinical workflow where it fits best for you. It delivers easy-to-interpret, actionable information in a single assessment.

The Oncoguard® Liver test is designed to be used in the clinical care pathway for at-risk patients.

 

exs-lvr-icon-patients-mf

Patients at risk for HCC
With Cirrhosis
Hepatitis B, C
Alcohol
Genetic hemochromatosis
Non-alcoholic fatty liver disease (NAFLD)
Stage 4 primary biliary cholangitis
Alpha-1-antitrypsin deficiency
Other causes of cirrhosis
Without Cirrhosis
Hepatitis B carriers (select)
HCC testing
workflow-graph

 

Adapted from AASLD guideline1

Please note that the Oncoguard® Liver test is not currently recommended as part of the AASLD guideline.

The Oncoguard® Liver test is intended for the qualitative detection of biomarkers associated with HCC and is indicated as an aid in the detection of HCC for adults with liver cirrhosis and/or chronic hepatitis B (HBV) who are at risk for HCC.

Chris-Conroy-Photography-2429-small

Consistency

A blood-based biomarker test like the Oncoguard® Liver test introduces a level of clarity and consistency you may not see with ultrasound assessments. Ultrasound sensitivity is often variable based on operator, equipment, and the patient’s overall morphology.1,2 Blood-based assessment offers consistency without concerns about patient weight, operator or equipment variability.

Convenience

The Oncoguard® Liver test requires a simple blood collection, enabling HCC testing from a single location. The convenience of a blood-based test may minimize the logistical challenges often encountered with traditional imaging procedures, helping more patients follow through with their care.

GettyImages-521848481-tuberemoved
content-image-18

exs-lvr-icon-journey

Let us help you get started

Contact the Customer Care Center at 1-844-870-8870 or fill out a form to request a visit with a representative.

References: 1. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. 2. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169-177. doi:10.1111/apt.13841 3. Samoylova ML, Mehta N, Roberts JP, et al. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018;24(9):1171-1177. doi:10.1002/lt.25202